Local drug delivery for percutaneous coronary intervention

Pharmacology and Therapeutics

Volumn 129, Issue 3, 2011, Pages 260-266

  Sharma, S ^a   Christopoulos, C ^a   Kukreja, N ^a   Gorog, D A ^a,b  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Bioabsorbable stents; Drug eluting balloon; Drug eluting stents; In stent restenosis; Local drug delivery; Percutaneous coronary intervention

Indexed keywords

ANGIOPEPTIN; ARGINYLGLYCYLASPARTIC ACID; CYTOCHALASIN D; DACTINOMYCIN; DEXAMETHASONE; DILTIAZEM; ESTRADIOL; EVEROLIMUS; FIBRIN; GOLD; HEPARIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; NOVOLIMUS; PACLITAXEL; PIMECROLIMUS; PLACEBO; POLYMER; PROBUCOL; RADIOACTIVE MATERIAL; RAPAMYCIN; SILVER; TACROLIMUS; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ARTERY GRAFT; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; BARE METAL STENT; BIODEGRADABLE IMPLANT; CONTROLLED DRUG RELEASE; COST CONTROL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; ENDOTHELIUM CELL; GOLD STANDARD; HUMAN; IN-STENT RESTENOSIS; LOADING DRUG DOSE; MATERIAL COATING; META ANALYSIS (TOPIC); NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; VEIN GRAFT;

EID: 79551682427     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.11.003     Document Type: Review

References (58)

1. M. Bertrand, E.P. McFadden, J.C. Fruchart, E. Van Belle, P. Commeau, and G. Grollier J Am Coll Cardiol 30 1997 863 869
2. Boccuzzi S.J., Weintraub W.S., Kosinski A.S., Roehm J.B., and Klein J.L. Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial) Am J Cardiol 81 5 1998 632 636
3. D. Brieger, and E. Topol Local drug delivery systems and prevention of restenosis Cardiovasc Res 35 3 1997 405 413
4. Byrne, R., Kastrati, A., Tiroch, K., Schulz, S., Pache, J., Pinieck, S., et al. (2010). 2-Year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor, drug-eluting stents. J Am Coll Cardiol 55(23), 2536-2543.
5. C. Cernigliaro, M. Sansa, G. Vitrella, A. Verde, A.S. Bongo, and L. Giuliani Preventing restenosis after implantation of bare stents with oral rapamycin: A randomized angiographic and intravascular ultrasound study with a 5-year clinical follow-up Cardiology 115 1 2010 77 86
6. Chevalier B., Silber S., Park S.J., Garcia E., Schuler G., and Serruys P.W. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: The NOBORI 1 trial-Phase 2 Circ Cardiovasc Interv 2 3 2009 188 195
7. A. Colombo, and E. Karvouni Biodegradable stents: Fulfilling the mission and stepping away Circulation 102 2000 371 373
8. B. Cortese The Piccoleto Trial presented at European Association of Percutaneous Cardiovascular Intervention, Barcelona, Spain 2009
9. Costa A., Sebate M., Van der Giessen W., Kay P., Cervinka P., and Ligthart J. Endovascular brachytherapy and late thrombotic occlusion Circulation 100 1999 789 792
10. Faxon D.P. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR Study J Am Coll Cardiol 25 2 1995, Feb 362 369
11. D.P. Faxon Systemic drug therapy for restenosis: "Déjà vu all over again" Circulation 106 2002 2296 2298
12. Fischman D.L., Leon M.B., Baim D.S., Schatz R.A., Savage M.P., Penn Ian The Stent Restenosis Study Investigators A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease N Engl J Med 331 1994 496 501
13. Geary R.L., Williams J.K., Golden D., Brown D.G., Benjamin M.E., and Adams M.R. Time course of cellular proliferation, intimal hyperplasia, and remodeling following angioplasty in monkeys with established atherosclerosis. A nonhuman primate model of restenosis Arterioscler Thromb Vasc Biol 16 1 1996 34 43
14. A.H. Gershlick Treating atherosclerosis: Local drug delivery from laboratory studies to clinical trials Atherosclerosis 160 2 2002 259 271
15. Gershlick A., De Scheerder I., Chevalier B., Stephens-Lloyd A., Camenzind E., and Vrints C. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial Circulation 3;109 4 2004 487 493
16. Goldman B., Blanke H., and Wolinsky H. Influence of pressure on permeability of normal and diseased muscular arteries to horseradish peroxidase Atherosclerosis 65 3 1987 215 225
17. Grube E., Silber S.M., and Eugene K. Taxus I: Prospective, randomized, double-blind comparison of NIRx stents coated with paclitaxel in a polymer carrier in de-novo coronary lesions compared with uncoated controls Circulation 104 suppl. II 2001 II 463 II-463. Abstract
18. Hamm C.W. PEPCAD III presented at American Heart Association scientific sessions, 14th November 2009
19. M. Hamon, E. Lécluse, J.P. Monassier, G. Grollier, and J.C. Potier Pharmacological approaches to the prevention of restenosis after coronary angioplasty Drug Aging 13 1998 291 301
20. Hausleiter J., Kastrati A., Mehilli J., Vogeser M., Zohlnhöfer D., and Schühlen H. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial Circulation 17; 110 7 2004 790 795
21. C. Herdeg, K. Gohring-Frischholz, K. Haas Karl, T. Geisler, C. Zurn, and U. Hartmann Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation Circ Cardiovasc Interv 2 4 2009 294 301
22. M.K. Hong, S.C. Wong, A. Farb, M.D. Mehlman, R. Virmani, and J.J. Barry Feasibility and drug delivery efficacy of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery Coron Artery Dis 4 1993 1023 1207
23. Huang Y., Venkatraman S., Boey F.Y.C., Lahti E.M., Umashankar P.R., and Mohanty M. In vitro and in vivo performance of a dual drug-eluting stent (DDES) Biomaterials 31 2010 4382 4391
24. Y. Huang, S.S. Venkatraman, F. Boey, P. Umashankar, M. Mohanty, and S. Arumugam The short-term effect on restenosis and thrombosis of a cobalt-chromium stent eluting two drugs in a porcine coronary artery model J Interv Cardiol 22 2009 466 478
25. B. Jørgensen, J. Bülow, M. Jørgensen, K. Tønnesen, J. Dalsgård Nielsen, and P. Holstein Femoral artery recanalisation with percutaneous angioplasty and segmentally enclosed plasminogen activator Lancet 333 8647 1989 1106 1108
26. A. Kastrati, H. Schuhlen, J. Hausleiter, H. Walter, E. Zitzmann-Roth, and M. Hadamitzky Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: Six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial Circulation 96 2 1997 462 467
27. C.A. Kavanagh, Y.A. Rochev, W.M. Gallagher, K.A. Dawsonc, and A.K. Keenan Local drug delivery in restenosis injury: Thermoresponsive co-polymers as potential drug delivery systems Pharmacol Ther 102 2004 1 15
28. C. Lambert, J. Leone, and S. Rowland Local drug delivery catheters: Functional comparison of porous and microporous designs Coron Artery Dis 4 5 1993 469 476
29. M. Leon, P. Teirstein, J. Moses, P. Tripuraneni, A. Lansky, and S. Jani Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting NEJM 344 2001 250 256
30. A.M. Lincoff, E.J. Topol, and S.G. Ellis Local drug delivery for the prevention of restenosis Fact Fancy Future Circ 90 1994 2070 2084
31. G. Maluenda, I. Ben-dor, C. Delhaye, M. Gonzalez, S. Collins, and R. Waksman Clinical experience with a novel intracoronary perfusion catheter to treat no-reflow phenomenon in acute coronary syndromes J Interv Cardiol 23 2 2010 109 113
32. S.O. Marx, and A.R. Marks Bench to bedside: The development of rapamycin and its application to stent restenosis Circulation 104 2001 852 855
33. Moodie G., Grantz S., and Martakos P. chapter 4 Camezind E. Deschreeder I. Local drug delivery for coronary artery disease: Established and emerging applications 2005 Taylor and Francis London & New York 28 46
34. Nabel E.G., Plautz G., Boyce F.M., Stanley J.C., and Nabel G.J. Recombinant gene expression in vivo within endothelial cells of the arterial wall Science 244 1989 1342 1344
35. J. Nebeker, R. Virmani, C. Bennett, J. Hoffman, M. Samore, and J. Alvarez Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project J Am Coll Cardiol 47 1 2006 175 181
36. Onuma Y. Presentation European Society of Cardiology meeting, Barcelona 31.8.2009
37. J.A. Ormiston, P.W. Serruys, E. Regar, D. Dudek, L. Thuesen, and M.W. Webster A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): A prospective open-label trial Lancet 371 9616 2008 899 907
38. S.J. Park, W.H. Shim, D.S. Ho, A.E. Raizner, S.W. Park, and M.K. Hong A paclitaxel-eluting stent for the prevention of coronary restenosis N Engl J Med 348 16 2003 1537 1545
39. C.F. Pereira, B. Rubilar, J. Mieres, O. Santaera, A.M. Rodriguez-Granillo, and A.E. Rodriguez Abstract 4538: Percutaneous Coronary Intervention with bare metal stents and oral Sirolimus has comparable safety and efficacy to treatment with drug eluting stents but with significant lower cost: 31 Months Cost Saving and Clinical Events Analysis from the Randomized, Controlled ORAR III (Oral Rapamycin in Argentina) Study Circulation 120 2009 S967
40. V.K. Raman, and E.R. Edelman Coated stents: Local pharmacology Semin Interv Cardiol 3 1998 133 137
41. E. Rowinsky, and R. Donehower Paclitaxel (Taxol) N Engl J Med 332 1995 1004 1014
42. Scheller B., and Speck U. Chapter 4 Scheller B. The drug coated balloon-History and clinical applications 2009 UNI-MED Verlag AG Germany 53
43. Schwartz R.S., Chronos N.A., and Virmani R. Preclinical restenosis models and drug-eluting stents: Still important, still much to learn J Am Coll Cardiol 6; 44 7 2004 1373 1385
44. Serruys P.W., Foley D.P., Höfling B., Puel J., Glogar H.D., and Seabra-Gomes R. Carvedilol for prevention of restenosis after directional coronary atherectomy: Final results of the European carvedilol atherectomy restenosis (EUROCARE) trial Circulation 4;101 13 2000 1512 1518
45. P. Serruys, F. Kiemeneij, C. Macaya, W. Rutsch, G. Heyndrickx, and H. Emanuelsson A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease NEJM 331 1994 489 495
46. P. Serruys, J. Ormiston, Y. Onuma, E. Regar, G. Gonzalo, and H. Garcia A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-Year outcomes and results from multiple imaging methods Lancet 373 2009 897 910
47. Sheiban I., Villata G., Bollati M., Sillano D., Lotrionte M., and Biondi-Zoccai G. Next-generation drug-eluting stents in coronary artery disease: Focus on everolimus-eluting stent (Xience V) Vasc Health Risk Manag 4 1 2008 31 38
48. P. Steg, L. Feldman, J. Scoazec, O. Tahlil, J. Barry, and S. Boulechfar Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector Circulation 90 4 1994 1648 1656
49. Stettler C., Wandel S., Allemann S., Kastrati A., Morice M.C., and Schomig A. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis Lancet 370 9591 2007 937 948 (Pubitemid 47393576)
50. H. Tamai, K. Igaki, E. Kyo, K. Kosuga, A. Kawashima, and S. Matsui Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans Circulation 102 4 2000 399 404
51. Tesfamariam B. Local vascular toxicokinetics of stent-based drug delivery Toxicol Lett 168 2007 93 102
52. M. Unverdorben, C. Vallbracht, and B. Cremers Paclitaxel coated balloon catheter versus paclitaxel-coated stent for treatment of coronary in-stent restenosis Circulation 119 2009 2986 2994
53. R. Virmani, and A. Farb Pathology of in-stent restenosis Curr Opin Lipidol 10 1999 499 506
54. R. Virmani, A. Farb, G. Guagliumi, and F.D. Kolodgie Drug-eluting stents: Caution and concerns for long-term outcome Coron Artery Dis 15 6 2004 313 318
55. R. Waksman, A.E. Raizner, A.C. Yeung, A.J. Lansky, and L. Vandertie The INHIBIT randomised controlled trial Lancet 359 2002 551 557
56. Whelan Mechanisms of drug loading and release kinetics Semin Interv Cardiol 3 1998 127 131
57. Wolinsky H., and Thung S.N. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery J Am Coll Cardiol 15 2 1990 475 481
58. Wykrzykowska J.J., Yoshinobu O., and Serruys P.W. Vascular Restoration Therapy: The fourth revolution in interventional cardiology and the ultimate "Rosy" prophecy EuroInterv Suppl 5 Supplement F 2009 F7 F8